BRAF and melanoma: It is also indicated in combination with dabrafenib for adjuvant treatment of patients with Stage III melanoma following complete resection, advanced non-small cell lung cancer, and locally advanced or metastatic anaplastic thyroid cancer with BRAF V600 mutation [3].